This session introduces the pharmacological basis of angiotensin-converting enzyme (ACE) inhibitors, building upon the physiological foundation of the renin–angiotensin–aldosterone system (RAAS). We will examine their mechanism of action, general pharmacodynamic and pharmacokinetic properties, and their broad therapeutic applications in cardiovascular and renal medicine. Emphasis will be placed on understanding the rationale for ACE inhibitor use in various clinical settings, rather than on memorizing individual drug profiles.

Learning Objectives:

• By the end of this lecture, participants should be able to:
• Explain the mechanism of action of ACE inhibitors in the context of the RAAS pathway.
• Identify the major physiological and clinical effects resulting from ACE inhibition.
• List the primary therapeutic indications for ACE inhibitors, including cardiovascular and renal conditions.
• Recognize the role of ACE inhibitors in reducing morbidity and mortality in key disease states.